{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:22:00Z","timestamp":1791174120109,"version":"4.1.0"},"reference-count":78,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":5859,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Generalized anxiety disorder (GAD) is a common (lifetime prevalence: 5.1%), recurrent condition, which often heralds other psychiatric disorders, notably depression. As by definition it is a disorder progressing over months, treatment should be designed on a long term basis. And yet, few studies have been conducted beyond the classical 6\u20138 weeks characterizing the acute treatment phase. This is especially true of anxiolytics, but also of antidepressants, with the exception of paroxetine and venlafaxine, which are the only drugs approved in this indication in Western countries. The efficacy of psychotherapy, notably relaxation and cognitive-behavioral therapy, is established in the treatment of GAD, but its preferred indications and possible combination with antidepressants are still to be specified. Long term, not to say very long term studies of GAD, as well as depression, will still be required in the future to improve its management and specify therapeutic modalities (combination treatment, optimal duration, continuous or intermittent therapy, choice of psychotherapeutic techniques or agents, \u2026). Early and adequately prolonged treatment should not only result in more numerous remission periods, but also in decreased frequency of co-morbidities whether depressive, addictive, or of another nature, and should also reduce the social impact of GAD.<\/jats:p>","DOI":"10.1016\/j.eurpsy.2004.01.001","type":"journal-article","created":{"date-parts":[[2004,3,13]],"date-time":"2004-03-13T10:12:36Z","timestamp":1079172756000},"page":"96-101","source":"Crossref","is-referenced-by-count":19,"title":["Long term therapy of generalized anxiety disorder"],"prefix":"10.1017","volume":"19","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Rouillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"S0924933800009512_ref74","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.69.6.875"},{"key":"S0924933800009512_ref72","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0305"},{"key":"S0924933800009512_ref71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1993.tb03405.x"},{"key":"S0924933800009512_ref70","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199305133281907","article-title":"Use of benzodiazepines in anxiety disorders.","volume":"328","author":"Shader","year":"1993","journal-title":"N Engl J Med"},{"key":"S0924933800009512_ref67","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.12.2008"},{"key":"S0924933800009512_ref63","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800290060008"},{"key":"S0924933800009512_ref60","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199002000-00014"},{"key":"S0924933800009512_ref59","doi-asserted-by":"publisher","DOI":"10.1016\/0887-6185(90)90026-6"},{"key":"S0924933800009512_ref57","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0508"},{"key":"S0924933800009512_ref56","first-page":"510","article-title":"Anxiety disorders in private practice psychiatric outpatients: prevalence comorbidity and burden","volume":"28","author":"Pelissolo","year":"2002","journal-title":"L\u2019Enc\u00e9phale"},{"key":"S0924933800009512_ref55","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.3.533"},{"key":"S0924933800009512_ref54","first-page":"5","article-title":"Dissolving the burden of generalized anxiety disorder.","volume":"62","author":"Ninan","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"S0924933800009512_ref49","first-page":"24","article-title":"Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations.","volume":"11","author":"Mohlman","year":"2003","journal-title":"Am J Geri-atr Psychiatry"},{"key":"S0924933800009512_ref48","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200212000-00013"},{"key":"S0924933800009512_ref52","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014549"},{"key":"S0924933800009512_ref69","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199305133281907","article-title":"Use of benzodiazepines in anxiety disorders.","volume":"328","author":"Shader","year":"1993","journal-title":"N Engl J Med"},{"key":"S0924933800009512_ref19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1037\/0022-006X.59.1.167","article-title":"Comparison of behaviour therapy in the treatment of generalized anxiety disorder.","volume":"59","author":"Butler","year":"1991","journal-title":"J Consult Clin Psychol"},{"key":"S0924933800009512_ref77","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.168.3.308"},{"key":"S0924933800009512_ref64","first-page":"9","article-title":"Pharmacotherapy of generalized anxiety disorder.","volume":"63","author":"Rickels","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"S0924933800009512_ref76","doi-asserted-by":"publisher","DOI":"10.1111\/j.0065-1591.2000.acp29-03.x"},{"key":"S0924933800009512_ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(02)00005-5"},{"key":"S0924933800009512_ref61","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03340060045024"},{"key":"S0924933800009512_ref39","first-page":"166","article-title":"Raising the expectations of long term treatment strategies in anxiety disorders.","volume":"36","author":"Keller","year":"2002","journal-title":"Psychopharmacol Bull"},{"key":"S0924933800009512_ref65","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb09660.x"},{"key":"S0924933800009512_ref50","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200102000-00011"},{"key":"S0924933800009512_ref31","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799001336"},{"key":"S0924933800009512_ref62","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1993.01820230054005"},{"key":"S0924933800009512_ref78","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.176.6.544"},{"key":"S0924933800009512_ref75","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.71.1.31"},{"key":"S0924933800009512_ref40","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950010008002"},{"key":"S0924933800009512_ref13","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.55.6.883"},{"key":"S0924933800009512_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(84)80048-9"},{"key":"S0924933800009512_ref25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1192\/bjp.165.3.315","article-title":"Cognitive therapy, analytic psychotherapy and anxiety management training for generalized anxiety disorder.","volume":"165","author":"Durham","year":"1994","journal-title":"Brit J Psychiatry"},{"key":"S0924933800009512_ref8","volume-title":"Anxiety disorders and phobias: a cognitive perspective.","author":"Beck","year":"1985"},{"key":"S0924933800009512_ref11","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.61.4.611"},{"key":"S0924933800009512_ref47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1034\/j.1600-0447.2000.101001029.x","article-title":"Generalized anxiety disorder (I.C.D.10) in primary care from a cross cultural perspective.","volume":"101","author":"Maier","year":"2000","journal-title":"A valid diagnostic entity? Acta Psychiat Scand"},{"key":"S0924933800009512_ref45","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200303000-00013"},{"key":"S0924933800009512_ref27","first-page":"3","article-title":"Buspirone in the long-term treatment of generalized anxiety disorder.","volume":"48","author":"Feighner","year":"1987","journal-title":"J Clin Psychiatry"},{"key":"S0924933800009512_ref14","first-page":"171","volume-title":"Long-term treatment for anxiety disorders.","author":"Borkovec","year":"1996"},{"key":"S0924933800009512_ref18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.151.4.535"},{"key":"S0924933800009512_ref17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00004850-199300830-00006","article-title":"A placebo controlled double blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorders","volume":"8","author":"Boyer","year":"1993","journal-title":"Int Clin Psychopharmacol"},{"key":"S0924933800009512_ref58","first-page":"289","article-title":"(a) Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care.","volume":"40","author":"Power","year":"1990","journal-title":"Brit J Gen Pract"},{"key":"S0924933800009512_ref3","first-page":"29","article-title":"Clinical guideslines for establishing remission in patients with depresssion and anxiety.","volume":"60","author":"Ballenger","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"S0924933800009512_ref41","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1176\/ajp.151.12.1760","article-title":"Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine.","volume":"151","author":"Klein","year":"1994","journal-title":"Am J Psychiatry"},{"key":"S0924933800009512_ref46","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1112"},{"key":"S0924933800009512_ref37","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1986.01800010081010"},{"key":"S0924933800009512_ref36","first-page":"293","article-title":"Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.","volume":"49","author":"Hoehn-Saric","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"S0924933800009512_ref66","unstructured":"[66] RUPPASG (Research Unit on Pediatric PsychopharmacologyAnxiety Study Group). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. Engl J Med 2001;344:1279\u201385."},{"key":"S0924933800009512_ref16","unstructured":"[16] Boyer, P Mah\u00e9, V Hackett, D et al. Efficacy of venlafaxine ER in social adjustment in patients with GAD. Presented at the 13th Annual Meeting of the ECNP Congress, Munich, 9\u201313 September 2000. 2000."},{"key":"S0924933800009512_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6185(02)00105-6"},{"key":"S0924933800009512_ref68","first-page":"9","article-title":"The long-term management of generalized anxiety disorder: issues and dilemmas.","volume":"57","author":"Schweizer","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"S0924933800009512_ref1","first-page":"15","article-title":"Venlafaxine extended-release (ER) in the treatment of generalized anxiety disorder.","volume":"179","author":"Allgulander","year":"2001","journal-title":"Twenty-four week placebo controlled dose ranging study. Brit J Psychiatry"},{"key":"S0924933800009512_ref2","first-page":"79","article-title":"Long-term treatment strategies in anxiety disorders.","volume":"36","author":"Allgulander","year":"2002","journal-title":"Psychopharmacol Bull"},{"key":"S0924933800009512_ref73","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200205000-00002"},{"key":"S0924933800009512_ref5","volume-title":"Anxiety and its disorders.","author":"Barlow","year":"1988"},{"key":"S0924933800009512_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7894(05)80221-7"},{"key":"S0924933800009512_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(87)90057-X"},{"key":"S0924933800009512_ref10","first-page":"207","article-title":"Efficacy and safety of a putative anxiolytic agent: ipsapirone.","volume":"26","author":"Borison","year":"1990","journal-title":"Psychopharmacol Bull"},{"key":"S0924933800009512_ref24","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291702007079"},{"key":"S0924933800009512_ref28","doi-asserted-by":"publisher","DOI":"10.1159\/000118565"},{"key":"S0924933800009512_ref4","first-page":"53","article-title":"Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression andAnxiety.","volume":"62","author":"Ballenger","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"S0924933800009512_ref12","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.56.6.877"},{"key":"S0924933800009512_ref15","first-page":"43","article-title":"Psychotherapy for generalized anxiety disorder.","volume":"62","author":"Borkovec","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"S0924933800009512_ref20","first-page":"93","article-title":"Long-term comparison of alprazolam, lorazepam and placebo in patients with anxiety disorder.","volume":"4","author":"Cohn","year":"1984","journal-title":"Psychophar-macotherapy"},{"key":"S0924933800009512_ref21","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199312000-00009"},{"key":"S0924933800009512_ref22","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0805"},{"key":"S0924933800009512_ref29","first-page":"785","article-title":"Advantages of hydroxyzine in generalized anxiety disorder: a double blind controlled versus placebo study.","volume":"20","author":"Ferreri","year":"1994","journal-title":"L\u2019Enc\u00e9phale"},{"key":"S0924933800009512_ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050731"},{"key":"S0924933800009512_ref23","doi-asserted-by":"publisher","DOI":"10.1177\/0145445500245002"},{"key":"S0924933800009512_ref26","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244440"},{"key":"S0924933800009512_ref30","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1077(199904)14:3<171::AID-HUP80>3.0.CO;2-7"},{"key":"S0924933800009512_ref33","first-page":"3082","article-title":"Efficacy of venlafaxine extended-release capsules in non depressed outpatients with generalized anxiety disorder.","volume":"283","author":"Gelenberg","year":"2000","journal-title":"A 6 month randomized controlled trial. JAMA"},{"key":"S0924933800009512_ref34","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1176\/ajp.156.11.1819","article-title":"Psychosocial treatment prescriptions for generalized anxiety disorder panic disorder and social phobia 1991\u20131996.","volume":"156","author":"Goisman","year":"1999","journal-title":"Am J Psychiatry"},{"key":"S0924933800009512_ref53","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.4.529"},{"key":"S0924933800009512_ref35","first-page":"671","article-title":"An open trial of nefazodone in adult patients with GAD.","volume":"32","author":"Hedges","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"S0924933800009512_ref38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50003.x"},{"key":"S0924933800009512_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(00)00357-8"},{"key":"S0924933800009512_ref44","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.68.6.957"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933804000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924933804000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933800009512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T03:30:54Z","timestamp":1682652654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933800009512\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0924933800009512"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2004.01.001","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}